Across TCGA pan-cancer cohorts, GALNT6 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GALNT6 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GALNT6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GALNT6 expression acts as an unfavorable survival marker.
LUSC and KICH are the cancer types where GALNT6 Mutation most reproducibly stratifies survival.